Antithrombin III and sepsis

Intensive Care Medicine

Volumn 24, Issue 7, 1998, Pages 649-650

  Mammen, E F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III;

DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; MULTIPLE ORGAN FAILURE; SEPSIS;

EID: 0031873130     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050639     Document Type: Editorial

References (15)

1. 1. MP Glauser G Zanetti JD Baumgartner J Cohen 1991 Septic shock: pathogenesis Lancet 338 732 736 1:STN:280:DyaK3MzmslShug%3D%3D 1679876 10.1016/0140-6736(91)91452-Z Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis. Lancet 338: 732–736
2. 2. CR Bone 1991 The pathogenesis of sepsis Ann Intern Med 115 457 469 1:CAS:528:DyaK38Xls1eksA%3D%3D 1872494 10.7326/0003-4819-115-6-457 Bone CR (1991) The pathogenesis of sepsis. Ann Intern Med 115: 457–469
3. 3. EF Mammen 1998 The haematological manifestations of sepsis J Antimicrobial Chemotherapy 41 Suppl A 17 24 1:CAS:528:DyaK1cXhtlWjt7w%3D 10.1093/jac/41.suppl_1.17 Mammen EF (1998) The haematological manifestations of sepsis. J Antimicrobial Chemotherapy 41[Suppl A]: 17–24
4. 4. R Balk T Emerson F Fourrier JA Kruse EF Mammen H-P Schuster H Vinaz-zer 1998 Therapeutic use of anti-thrombin concentrate in sepsis Semin Thromb Hemostas 24 183 194 1:CAS:528:DyaK1cXmvVWlsrg%3D 10.1055/s-2007-995839 Balk R, Emerson T, Fourrier F, Kruse JA, Mammen EF, Schuster H-P, Vinaz-zer H (1998) Therapeutic use of anti-thrombin concentrate in sepsis. Semin Thromb Hemostas 24:183–194
5. 5. RM Mesters N Flörke H Ostermann J Kienast 1996 Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis Thromb Haemostas 75 902 907 1:CAS:528:DyaK28XktVOlt7g%3D Mesters RM, Flörke N, Ostermann H, Kienast J (1996) Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemostas 75: 902–907
6. 6. JA Lorente LJ Garcia-Frade L Landin R Pablo de C Torrado E Renes 1993 Time course of hemostatic abnormalities in sepsis and its relation to outcome Chest 103 1536 1542 1:STN:280:DyaK3s3ltFykug%3D%3D 8486040 10.1378/chest.103.5.1536 Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E (1993) Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103:1536–1542
7. 7. EF Mammen 1992 Diagnosis of disseminated intravascular coagulation and related consumptive coagulopathies Caduceus Medical Publishers Patterson, NY Mammen EF (1992) Diagnosis of disseminated intravascular coagulation and related consumptive coagulopathies. Caduceus Medical Publishers, Patterson, NY
8. 8. EF Mammen 1998 Antithrombin: its physiological importance and role in DIC Semin Thromb Hemostas 24 19 25 1:CAS:528:DyaK1cXnslSnurY%3D 10.1055/s-2007-995819 Mammen EF (1998) Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemostas 24: 19–25
9. 9. T Yamauchi F Umeda T Inoguchi H Nawata 1989 Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells Biochem Biophys Res Commun 29 1404 1411 10.1016/0006-291X(89)91135-2 Yamauchi T, Umeda F, Inoguchi T, Nawata H (1989) Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 29: 1404–1411.
10. 10. K Okijama 1996 New therapeutic implications of antithrombin III replacement in disseminated intravascular coagulation and multiple organ failure Intensivmedizin 33 5 11 Okijama K (1996) New therapeutic implications of antithrombin III replacement in disseminated intravascular coagulation and multiple organ failure. Intensivmedizin 33: 5–11
11. 11. M Jochum 1995 Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation Semin Hematol 32 Suppl 2 19 32 1:CAS:528:DyaK28Xht12gs7c%3D 8821206 Jochum M (1995) Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol 32[Suppl 2]:19–32
12. 12. F Fourrier C Chopin J Huart I Runge C Caron J Goudemand 1993 Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation Chest 104 882 888 1:STN:280:DyaK3szntlOlsg%3D%3D 8365305 10.1378/chest.104.3.882 Fourrier F, Chopin C, Huart J, Runge I, Caron C, Goudemand J (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104: 882–888
13. 13. Schuster H-P, Mathias FR (1995) Antithrombin III in severe sepsis. 15th Int Symp Intensive Care Emerg Med, Brussels (Abst).
14. 14. D Guidici G Gallioli A Wolfler 1997 AT III in the ICU patient: a randomized double blind trial A Braschi M Chiaranda L Gattinoi A Pesenti F Raimondi Simposio Mostra Anestesia Reanimazione e Therapia Intensiva Springer Berlin Heidelberg New York Tokyo 9 12 Guidici D, Gallioli G, Wolfler A (1997) AT III in the ICU patient: a randomized double blind trial. In: Braschi A, Chiaranda M, Gattinoi L, Pesenti A, Raimondi F (eds) Simposio Mostra Anestesia Reanimazione e Therapia Intensiva. Springer, Berlin Heidelberg New York Tokyo, pp 9–12
15. 15. GR Bernard 1995 Sepsis trials, intersection of investigation, regulation, funding, and practice Am J Resp Crit Care Med 152 4 10 1:STN:280:DyaK2MzitlajtA%3D%3D 7599855 10.1164/ajrccm.152.1.7599855 Bernard GR (1995) Sepsis trials, intersection of investigation, regulation, funding, and practice. Am J Resp Crit Care Med 152: 4–10